VarmX raises €12.5 million to develop modified blood coagulation factor X for treating severe bleeding in patients using anticoagulants
Funding enables clinical stage trials of lead compound PseudoXa € 7.5 million Series A financing from lead investor BioGeneration Ventures (BGV) and Dutch regional development company InnovationQuarter Financing supplemented by € 5.0 million innovation credit from the...
Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ImmunoGen
AMSTERDAM, NETHERLANDS – May 14, 2018 – Synaffix B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of Dr. John M. Lambert, the former Chief Scientific Officer of ImmunoGen, Inc. Dr. Lambert joined ImmunoGen Inc. in 1987 and...
Scenic Biotech: one of Nature Biotechnology Academic Spinouts of 2017
We congratulate Scenic Biotech on being one of Nature Biotechnology Academic Spinouts of 2017. Nature Biotechnology: "... we believe these companies represent some of the best (and most richly financed) science that was commercialized from academia in 2017". Please...
Escalier Biosciences Raises $19 Million to Develop its Topical and Systemic RORγt Therapies for Psoriasis and other Autoimmune Diseases
Advancing Escalier’s drug candidates through human proof-of-concept studies NIJMEGEN, The Netherlands and ENCINITAS, California, – Escalier Biosciences BV, a privately held biopharmaceutical company, today announced the closing of a $19 million Series B financing. The...
BGV co-leads €25 million Series A fundraising in NorthSea Therapeutics and its promising NASH drug programme
Lead drug icosabutate, in-licensed from Pronova BioPharma AS Phase IIb-ready at the end of 2018 Investment syndicate led by Forbion and BGV, and includes Novo Seeds and New Science Ventures Naarden, The Netherlands, 12 December 2017 – BGV, an early stage European...
Synaffix Launches toxSYN™, a New Platform of ADC Payloads
AMSTERDAM, NETHERLANDS – December 6, 2017 – Synaffix BV, a biotechnology company that has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates (ADCs), today announced the launch of a new platform of...
Synaffix Commands IP Space of Glycan-Conjugated ADCs Through Major Expansion of Granted Patent Portfolio
AMSTERDAM, NETHERLANDS – November 29th, 2017 – Synaffix BV, a biotechnology company that has developed a proprietary site-specific platform technology to enable differentiated antibody-drug conjugates (ADCs), today announced the granting of a key patent that...
Dutch Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials
Maastricht, The Netherlands, 28 November 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced that it secured a €2.5...
Cristal Therapeutics Progresses Nanomedicine CriPec®-docetaxel to Phase 1b Development in Patients with Solid Tumours
Maastricht, The Netherlands, 1 November 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announced today that it has begun a Phase 1b...
BGV Fund III reaches EUR 82 million in final close: Investments from Bristol-Myers Squibb and Johnson & Johnson Innovation – JJDC
BioGeneration Ventures (BGV) closes its third fund, BGV III, at EUR 82 million exceeding its target to accommodate strong interest from private, institutional and strategic investors Bristol-Myers Squibb and JJDC back European early stage innovation by investing in...